Parsatzumab (EGFL7) - Research Grid Biosimilar
Gecertificeerd

Parsatzumab (EGFL7) - Research Grid Biosimilar

Catalog #: 10-499
Maat: 0.1 mg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100
Technische Documentatie

Technische Specificaties

Background

Parsatuzumab is under investigation in clinical trial NCT01366131, Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) .

Immunogen

Humanized / EGFL7 [Homo sapiens]

Clonality

• Recombinant Monoclonal

Conjugation

Unconjugated

Type

Primary Antibodies, Biosimilars

Source

CHO cells

Field of Research

Cancer

Purification

>95%

Concentration

Batch dependent

Buffer

PBS buffer pH7.5

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

Fragment

IgG1-kappa

NCBI Organism

Homo sapiens

Other Product Names

RG7414, RO5490248

Beschrijving

Parsatzumab (EGFL7) - Research Grid Biosimilar Beschikbaar in 0.1 mg. Bestel eenvoudig online met snelle levering.

Specificaties

ProductnaamParsatzumab (EGFL7) - Research Grid Biosimilar
Categorie
Beschikbare grootte0.1 mg
Catalogusnummer10-499